Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft.
Level 5 - mechanism / opinion, no new human data
Preclinical animal research (pig-to-baboon xenotransplantation)
PubMed 27045379 · doi:10.1038/ncomms11138
What was done
Cardiac xenografts from donor pigs with three genetic modifications (alpha 1-3 galactosyltransferase knockout, expressing human CD46 and human thrombomodulin; GTKO.hCD46.hTBM) were transplanted into baboons. The recipient immunomodulatory regimen comprised induction with anti-thymocyte globulin and anti-CD20 antibody, followed by maintenance therapy with mycophenolate mofetil and intensive dosing of a chimeric anti-CD40 (2C10R4) antibody.
What was found
In five consecutive baboon recipients, cardiac xenograft survival reached a median of 298 days and a maximum of 945 days, compared to the group's historical benchmarks of 180 and 500 days. Tapering or reducing the anti-CD40 antibody dose at day 100 or after 1 year resulted in recurrence of anti-pig antibodies and graft failure.
Why it matters
The study shows that genetic modifications paired with sustained anti-CD40-mediated costimulation blockade can consistently prevent humoral rejection and systemic coagulation dysregulation, supporting primate cardiac xenograft survival beyond 900 days.
Limits
The study is restricted to a small animal sample size (n = 5 baboons) and cannot establish clinical safety or efficacy in humans. Long-term graft survival was dependent on continuous intensive immunosuppression, with dose reductions triggering graft failure.
Cited by
- supports Non-human primates receiving germline gene-edited pig organ transplants have achieved survival times of approximately 500 to 600 days.